Figure 6.

iNDV3α-LP treatment enhances antitumor immunity. (A and B) CTL response using B16 (A) and 4T1 (B) as target cells and the splenocytes from the mice treated with the indicated formulations as effector cells. (C and D) The in vivo CTL response was examined by injecting CFSE-labeled B16 (D) or 4T1 cells into the mouse abdomen treated with the indicated formulations to analyze the proliferation of CD45⁻ tumor cells by FCM and calculate the percentage of cell lysis (C, see also online supplemental figure S1). (E–G) The percentage of CD8⁺ splenocytes secreting IFN-γ (E), TNF-α (F), and IL-2 (G) from B16- or 4T1-bearing mice treated with the indicated formulations. (H) The synergistic indexes (SIs) calculated with the mean percentage of CD8⁺ cell subtypes in (E–G). (I) Western blot detection of the tumor-specific IgG in the serum from mice treated with the indicated formulations. (J and K) ELISPOT detection of the splenocytes secreting IgG specific to B16 or 4T1 cells (J) and the average number of IgG-secreting cells in 10⁵ splenocytes (K). (L and M) The IgG titer in the serum from B16-bearing or 4T1-bearing mice treated with the indicated formulations (L) and the IgG subtypes (M). ELISPOT, enzyme-linked immunospot; iNDV3α-LP, iRGD-liposome loaded with NDV expressing MIP-3α.